Volume | 1 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Homology Medicines Inc | FIXX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.5599 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 1 | - | 0.458 - 1.76 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:00:01 | 1 | $ 0.5599 | USD |
Homology Medicines Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
32.44M | 57.93M | - | 3.21M | -5.01M | -0.09 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Homology Medicines News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FIXX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.5361 | 0.566 | 0.51 | 0.5453497 | 231,738 | 0.0238 | 4.44% |
1 Month | 0.9904 | 1.0622 | 0.458 | 0.6414723 | 682,069 | -0.4305 | -43.47% |
3 Months | 1.16 | 1.24 | 0.458 | 0.7880929 | 327,417 | -0.6001 | -51.73% |
6 Months | 0.97 | 1.48 | 0.458 | 1.01 | 330,889 | -0.4101 | -42.28% |
1 Year | 1.51 | 1.76 | 0.458 | 1.07 | 235,134 | -0.9501 | -62.92% |
3 Years | 9.80 | 15.24 | 0.458 | 5.07 | 395,367 | -9.24 | -94.29% |
5 Years | 23.55 | 31.80 | 0.458 | 9.04 | 365,140 | -22.99 | -97.62% |
Homology Medicines Description
Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. |